BigBear.ai vs. IonQ: Which Technology Stock Is a Better Buy in 2026?
Axe Cap view
IonQ Edges Out BigBear.ai for Patient Investors
Between two speculative US tech plays, IonQ’s growth and diversity make it more compelling than BigBear.ai’s government-reliant AI contracts.
BigBear.ai’s heavy dependence on a few government customers—over half its revenue—raises red flags, especially as revenue recently declined nearly 20%. Operational improvements are encouraging, yet the cash burn and accounting issues suggest caution. IonQ's quantum tech is in much earlier stages but shows impressive revenue growth above 200%, backed by broader customer exposure and international reach. For South African investors tempted by US tech risk, the better proxy might be to watch USD/ZAR closely since these companies don’t have direct JSE exposure. That said, IonQ’s commercial partnerships align it better for long-term gains despite a very high burn rate. This view could be wrong if BigBear.ai lands substantial new contracts or if IonQ’s tech roadmap falters amid stiff competition. The rand fluctuates heavily on global risk appetite, so consider currency risk when eyeing these speculative names—especially since a weaker rand lifts dollar-based returns but increases volatility. this is just our opinion and not financial advice
Avoid BigBear.ai due to overreliance on a shrinking customer base and accounting concerns. For those patient on quantum computing’s future, a small, speculative position in IonQ makes sense, but keep stops tight given execution risks and FX volatility.
- USD/ZAR
- IONQ
- BigBear.ai failing to diversify customers or improve profitability
- IonQ facing technological setbacks or capital raising challenges
5/10
The article compares two early-stage, unprofitable tech companies: BigBear.ai, which provides AI solutions to U.S. government agencies, and IonQ, a quantum computing pioneer. BigBear.ai faces declining revenue and dangerous customer concentration (51% from customers over 10%), while IonQ shows triple-digit revenue growth but massive cash burn. The author recommends IonQ for patient investors due to its more diversified customer base and expanding commercial opportunities, despite both being speculative bets.
Our take is based on reporting first published by The Motley Fool.